Sales Marketing

PAUL A. BARTOLOTTA ** Buttonwood Drive, Long Valley, NJ 07853

908-***-**** **********.****@*****.***

SENIOR LEADER

International & Domestic

Corporate Analysis Market Analysis Strategic Planning Competitive Intelligence

Turnarounds Acquisitions Strategic Partnering Business Development Financial Modeling

Product Development Revenue Growth P&L Budgeting Negotiations Cost Containment

PROFESSIONAL EXPERIENCE

PAUL A. BARTOLOTTA & ASSOCIATES, Long Valley, NJ 2009 – Present

Pharmaceutical industry consulting

President

Consulting by project assignment to MC Access (managed care business)

• Researching and analyzing various therapeutic areas as they pertain to the managed markets.

• Securing new business development opportunities with pharmaceutical clients.

SANOFI - AVENTIS PHARMACEUTICALS, Bridgewater, NJ 2005 to 2008

A $25 billion pharmaceutical company

Director – North American Business

Worked in the Office of the President & CEO of North American operations.

• Managed client relations for all major accounts. Ensured client satisfaction with all products and developed new demand for

additional profitability.

• Provided solutions and strategies to the sales force to enhance performance. Assisted sales force with closing major accounts.

• Conceived and implemented marketing strategies to assist the marketing department. This function involved creating niche markets

for some of the products.

• Coordinated activities between the brand teams and advertising agencies, ensuring that timelines were adhered to and arbitrated

disputes among the players. Reviewed final copy.

• Consulted to the executive team on operational strategy of the Canadian affiliate, and also focused on sales and marketing.

• Oversaw integration activities in respect to the merger of Sanofi and Aventis to ensure smooth transition. Focused on sales and

marketing, promoting open and positive communications.

• Led team to in-license Eloxatin (colon cancer) and developed a successful marketing strategy.

• Developed successful marketing strategy for Taxotere…the only chemotherapy indicated for use in five types of cancer.

PAUL A. BARTOLOTTA & ASSOCIATES, Long Valley, NJ 2004

Pharmaceutical industry consulting

President

Consulted by project assignment in the integration efforts of Sanofi-Synthelabo and Aventis (see above).

• Studied and analyzed products and therapeutic areas for possible divestment.

• Created strategic plans for future operations of an Aventis division.

PHARMACIA CORPORATION, Peapack, NJ 1998 to 2003

A $15 billion global pharmaceutical company

Executive Director – Global Pharmaceutical Business, 2000-2003

Senior Director – Global Pharmaceutical Business, 1998-2000

Key advisor and problem solver for Tim Rothwell, the President of Global Pharmaceutical Business (GPB). Developed

numerous business plans and conducted business reviews with GPB’s president, as a senior member of the Operations Team.

Led on-going support activities for global business functions. Supervised teams ranging in size from 10 to 30 professionals.

• GPB’s lead in collaboration with other Pharmacia business entities in relation to business development, in-licensing product

opportunities, and internal product development programs. Developed a system to implement and manage market country

participation in product development programs. Liaised with cross-functional Licensing Lead Generation Teams. Researched,

analyzed and assessed business opportunities for partnering in other firms’ product development programs.

• Instrumental in effectuating the in-licensing of key products for arthritis, COPD and prostate cancer. Key advisor in the acquisition

of a biotech company with an anti-angiogenesis product.

• GPB’s liaison in major cross-functional initiatives. Lead member of Global Information Network team that generated millions in

cost savings while delivering research services in a more comprehensive, user-friendly manner on a global scale. Managed all

business divestment activities at the market country level, and consulted in corporate partnering arrangements.

• Provided proactive support and guidance to all core market countries (Western Europe and Japan). Reviewed, analyzed and

developed recommendations on new business activity. Helped launched two key products in Japan for the treatment of OAB and

resistant strains of bacteria. Reviewed, evaluated and assisted in the presentation of significant issues (i.e., pricing impact,

reimbursement policy changes) to regulatory bodies.

• Developed specific expertise for unique market country applications (Western Europe and Japan) including political, regulatory,

economic, sociologic and competitive business issues. Managed the development and strategic analysis of GPB’s capabilities data.

• Created and issued two key monthly management reports. The Significant Events Report provided complete but brief, up-to-the-

minute views on the global industry including corporate financial, political, regulatory, economic and general interest issues. The

Core Countries Report (Western Europe and Japan) provided views on performance inclusive of YTD sales figures, sales notes,

market shares and new product launches.

• Led team to in-license Trelstar (prostate cancer) and developed a successful marketing strategy.

BALDWIN VENTURES, INC., White Plains, NY 1991 to 1997

A $3 million, privately owned consulting firm to the pharmaceutical industry

Chief Executive Officer/President

Full P&L and development responsibility including sourcing new clients, development of programs and proposals,

marketing, administration, stockholder relations, and finance. Owned 60% of the firm.

• Consulted on new business development, conducted broad-based and specific industry studies, strategic planning (i.e. brand

defense strategies), technology assessment, competitive market analysis, due diligence studies for mergers and acquisitions,

business valuations, various opportunities analysis, and product analysis.

• Created a successful strategic plan for the geriatrics division of a major pharmaceutical company. Plan forecast net profits of $400

million over a 4-year period.

• Developed a strategic plan (net profit of $250 million over seven years) for a new corporate focus in prescription pediatric

medicines, and analysis of the O-T-C market strategy for pediatric drugs.

• Provided venture capital opportunities to young and emerging biotechnology and pharmaceutical firms on behalf of major

pharmaceutical clients. Created plan for the $100 million fund.

JACKSON STEEL PRODUCTS, Mineola, NY 1988 to 1991

A $10 million family owned manufacturer of specialty rolled steel products

President

Full P&L responsibility in a successful turnaround of a failing company. Directed all functions including product

development, marketing/sales, manufacturing, operations, finance and administration.

• Conceived and implemented new corporate structure. Identified niche market, created new product line, and recruited and trained

management. Annual sales increased 20% each year.

• Raised additional capital with investors, automated plant operations, negotiated significantly lower prices for raw materials,

developed shipping efficiencies, and improved relations with the union.

SAGE ADVERTISING INC., New York, NY 1985 to 1988

A $5 million media company specializing in corporate presentations

President

Full operational responsibility in a successful turnaround including sales/marketing, financing, human resources,

administration, IT, and procurement.

• Hired by private owner to rescue company. Created a new market and direction for the company.

• Personally identified and negotiated a major account in the pharmaceutical industry (Novartis).

EDUCATION

J.D., College of William and Mary Law School, Williamsburg, VA (passed New York bar exam)

B.A., Political Science and Economics, Drew University, Madison, NJ

Contact this candidate